Correlation Between Neurobo Pharmaceuticals and Pmv Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Neurobo Pharmaceuticals and Pmv Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurobo Pharmaceuticals and Pmv Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neurobo Pharmaceuticals and Pmv Pharmaceuticals, you can compare the effects of market volatilities on Neurobo Pharmaceuticals and Pmv Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurobo Pharmaceuticals with a short position of Pmv Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurobo Pharmaceuticals and Pmv Pharmaceuticals.

Diversification Opportunities for Neurobo Pharmaceuticals and Pmv Pharmaceuticals

0.59
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Neurobo and Pmv is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Neurobo Pharmaceuticals and Pmv Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pmv Pharmaceuticals and Neurobo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurobo Pharmaceuticals are associated (or correlated) with Pmv Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pmv Pharmaceuticals has no effect on the direction of Neurobo Pharmaceuticals i.e., Neurobo Pharmaceuticals and Pmv Pharmaceuticals go up and down completely randomly.

Pair Corralation between Neurobo Pharmaceuticals and Pmv Pharmaceuticals

Given the investment horizon of 90 days Neurobo Pharmaceuticals is expected to under-perform the Pmv Pharmaceuticals. In addition to that, Neurobo Pharmaceuticals is 2.07 times more volatile than Pmv Pharmaceuticals. It trades about -0.08 of its total potential returns per unit of risk. Pmv Pharmaceuticals is currently generating about -0.03 per unit of volatility. If you would invest  149.00  in Pmv Pharmaceuticals on October 24, 2024 and sell it today you would lose (12.00) from holding Pmv Pharmaceuticals or give up 8.05% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy88.89%
ValuesDaily Returns

Neurobo Pharmaceuticals  vs.  Pmv Pharmaceuticals

 Performance 
       Timeline  
Neurobo Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Neurobo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Pmv Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Pmv Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Neurobo Pharmaceuticals and Pmv Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Neurobo Pharmaceuticals and Pmv Pharmaceuticals

The main advantage of trading using opposite Neurobo Pharmaceuticals and Pmv Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurobo Pharmaceuticals position performs unexpectedly, Pmv Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pmv Pharmaceuticals will offset losses from the drop in Pmv Pharmaceuticals' long position.
The idea behind Neurobo Pharmaceuticals and Pmv Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Complementary Tools

Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance